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1. Introduction 
It is widely accepted that manifestation of target organs damage in patients with metabolic 
syndrome (MS) often has simultaneous and rapid pattern. Non-alcoholic fatty liver disease 
(NAFLD) has been described as one of metabolic syndrome-induced target organ damage. 
NAFLD clinical manifestations vary from ultrasonographically detected liver steatosis to 
non-alcoholic steatohepatitis (NASH) (Sowers, 2008). Detailed analysis of NAFLD 
relationship with other organs impairment in MS patients is particularly important for 
diagnostic procedures adjustment and optimization of treatment. 
Different experimental and clinical research data demonstrate strict relation between 
NAFLD and chronic kidney disease (CKD). In a population study including more than 8,000 
healthy men, recruited in South Korea, NAFLD with elevated serum gamma-
glutamyltransferase (GGT) concentration was associated with an increased CKD risk among 
nondiabetic, nonhypertensive men, irrespective of metabolic syndrome. The association was 
evident even after adjustment for age, glomerular filtration rate (GFR), triglycerides, and 
high-density lipoprotein cholesterol (Chang et al., 2008). Another study data suggested that 
NAFLD is associated with an increased prevalence of CKD in type 2 diabetic individuals 
independent from numerous baseline confounding factors (Targher et al., 2008). 
Presence of association between NAFLD and CKD revealed similar risk factors and rate of 
their coexistence in MS patients and could be explained by similar development 
mechanisms. Multiple mediators known as adipokines expressed are secreted by adipocytes 
and play an important role in the induction of endothelial dysfunction, tissue hypertrophy 
and fibrosis even at an early stage of target organ damage (Antuna-Puente et al., 2008). Pair 
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of adipokines – leptin and adiponectin are physiological antagonists. Combination of leptin 
hyperproduction and peripheral tissues resistance to it in patients with abdominal type of 
obesity is paired with protector insufficiency – adiponectin. It leads to progression of 
dysmetabolism, particularly insulin resistance development and organ remodeling 
intensification (Anubhuti & Arora, 2008; Han et al., 2009). Obstructive sleep apnea 
syndrome (OSAS) could be integral pathogenetic chain in CKD and NAFLD (Tokuda et al., 
2008). Investigation of correlation between plasma leptin and adiponectin concentrations, 
OSAS and CKD development in NAFLD patients gives opportunity to get closer to 
mechanisms of target organs damage in MS with subsequent optimization of prophylactic 
strategy. 
2. Materials and methods 
Research involved 86 patients (64 males and 22 females) with MS diagnosed according to 
standard criteria (Alberti et al., 2006) and NAFLD (ultrasonic proven liver steatosis in 
combination with elevated transaminases, GGT and/or alkaline phosphatase level increase 
without signs of viral hepatitis or other diseases with hepatic manifestation). 
All the patients had abdominal obesity (waist circumference (WC) >94 cm in males and >80 
cm in females (Alberti et al., 2006)). Mean age was 44.0±11.0. 
Along with general investigation all patients were tested for common risk factors presence 
and severity (Mancia et al., 2009). Blood pressure was measured using a standard mercury 
sphygmomanometer under standard conditions as mentioned in cardiovascular survey 
methods. Each person was examined for height, weight and WC without shoes with 
minimal clothing as per cardiovascular survey methods. Body mass index (BMI) was 
calculated by formula of weight in kg/height m2. All patients underwent biochemical tests: 
concentrations of HDL cholesterol, LDL cholesterol, VLDL cholesterol, total cholesterol and 
triglycerides (Biosystems S.A. kit, Spain) were measured on automatic analyzer Beckman 
Synchron Clinical System CX5delta; also atherogenic index was calculated using equation: 
atherogenic index = (total cholesterol – HDL cholesterol) / HDL cholesterol. 
Presence and grade of insulin resistance and disturbances of carbohydrates metabolism 
related to it were estimated by fasting serum glucose level (Biosystems S.A. kit, Spain), C-
peptide (D『』 kit, USA), fasting insulin serum concentration (D『』 kit, USA) and HOMA-
index calculation (fasting glucose (mmol/L) x insulin (IU/mL) / 22.5). 
Plasma concentration of adipokines – leptin and adiponectin were measured by immune-
enzyme analysis (“Human Adiponectin ELISA” (BioVendor GmbH, Germany), “Leptin 
(Sandwich) Elisa” (DRG, USA)). 
Signs of target organs damage were registered according to standard recommendations 
(Alberti et al., 2006): left ventricular hypertrophy was diagnosed echocardiographically 
using Sokolow-Lyon criteria and left ventricular mass index (Acuson Sequoia 512 (Siemens 
Acuson, USA)); atherosclerotic involvement of carotid artery was diagnosed by ultrasonic 
investigation of carotid artery intima-media thickness (CIMT) and/or by detection of 
atherosclerotic plaque in its wall (ESAOTE (Technos MPX, Italy)); albuminuria was 
estimated using nephelometric assay (Immage Immunochemistry Systems, Beckman 
Coulter, USA), GFR was estimated using MDRD formula. 
For statistical processing data were analysed by STATISTICA 8.0 (StatSoft, Russia). Various 
numbers are given as mean value and standard deviation (for normal distribution); median 
value and interquartile range (for asymmetric distribution). Categorical variables have been 
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compared by parametric and nonparametric methods. The Pvalue < 0.05 was considered as 
significant. 
3. Results 
Patients were divided into two groups depending on stage of NAFLD: 48 subjects with 
clinically unsuspected liver steatosis detected only by ultrasonic investigation and 38 
subjects with signs of NASH. Transaminases and G-GT serum levels were comparatively 
higher in patients with NASH (Table 1), whereas De Ritis ratio was comparatively higher in 
patients with liver steatosis. 
 
 NASH(n=38) Liver steatosis (n=48) 
AST, IU/mL 54±31* 24±8 
ALT, UI/mL 99±73* 32±17 
De Ritis ratio 0.6±0.2* 0.8±0.2 
G-GT, IU/mL 97±65* 47±30 
Table 1. Serum AST, ALT, G-GT levels and De Ritis ratio in patients with MS and NAFLD 
(n=86). * P<0.001 
Comparison of CKD and NASH prevalence rate according to number of damaged target 
organs revealed that both CKD and NASH prevalence was significantly higher in group of 
patients with >3 target organ damage (Table 2) and lower in other groups (patients with 1 or 
2 target organ damage). The patients with 2 and >3 target organ damage showed significant 
increase in albuminuria level. There was no significant difference in plasma concentrations 
of adiponectin and leptin in all the groups, but ratio leptinemia/adiponectinemia increased 
significantly in concordance with number of damaged target organ and reached maximum 
in patients with >3 target organ damage. 
 
 
 1 target organ 
damage (n=18) 
2 target organ 
damage (n=39) 
>3 target organ 
damage (n=18) 
CKD rate, % 17% 
P<0.05 vs 2 и >3 
44% 67% 
NASH rate, % 39% 
P<0.05 vs >3 
44% 78% 
P<0.05 vs 2 
Albumiuria, mg/24h 6.0 (4.3 – 9.0) 
P<0.05 vs 2 and >3 
12.6 (8.0 – 38.0) 30.2 (17.3 – 48.0) 
Leptin, ng/mL 23.6+23.4 31.6+27.3 31.2+26.0 
Adiponectin, μg/mL 31.3+17.5 22.9+20.2 11.8+5.5 
Leptin/Adiponectin 1.0+0.8 
P<0.05 vs 2 and >3 
1.7+1.4 3.1+1.6 
P<0.05 vs 2 
Table 2. CKD and NASH prevalence, albuminuria and adipokines plasma concentration in 
patients with MS and NAFLD (n=86). 
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Among all patients with MS and NASH 37.2% (32 patients) were diagnosed CKD, 26 of 
them had microalbuminuria, 6 subjects had urinary albumin excretion over 300 mg/24h. 
Five patients had CKD III stage (GFR <60 mL/min/1.73m2), all of them also had signs of 
NASH. Patients with MS, NAFLD and CKD showed marked insulin resistance: fasting 
insulinemia level, HOMA index and plasma C-peptide concentration in this type of patients 
were higher than in patients with NAFLD without CKD (Table 3). Moreover in patients with 
MS, NAFLD and CKD registered significantly higher plasma leptin level.  
 
 
Patients with CKD 
(n=32) 
Patients without CKD 
(n=54) 
Insulin, μU/mL 16.8±9.2 11.5±5.6** 
HOMA index 4.2±2.2 2.9±1.5** 
C-peptide, pmol/L 1326±411 999±341*** 
Leptin, ng/mL 38.2±28.8 21.6±19.8* 
Adiponectin, μg/mL 23.7±19.5 18.1±14.8 
Leptin/Adiponectin 2.15±1.58 1.71±1.52 
Table 3. Comparison of insulin resistance and plasma adipokines levels in patients with MS 
and NAFLD in case of CKD presence or absence. *-P=0.003; **-P=0.002; ***-P<0.001. 
Correlation analysis showed direct correlation of leptin concentration and BMI, systolic 
blood pressure, adiponectin level and albumiuria (Table 4). Adiponectin level correlated 
directly with leptin level, serum HDL cholesterol concentration and De Ritis ratio. Inverse 
correlation was registered between atherogenic index, CIMT and serum level of adiponectin. 
 
Parameter Leptin Adiponectin 
BMI r = 0.27* r = 0.29  
WC r = 0.21  r = 0.33  
Systolic blood pressure r = 0.24* r = 0.10  
Atherogenic index r = -0.14  r = –0.43* 
HDL cholesterol r = 0.18  r = 0.43* 
CIMT r = -0.04  r = -0.38* 
HOMA index r = 0.32* r = -0.18  
C-peptide r = 0.29* r = -0.02  
Insulin r = 0.35* r = -0.10  
De Ritis ratio r = 0.13  r = 0.36* 
Leptin - r = 0.39* 
Adiponectin r = 0.39* - 
Albuminuria r = 0.28* r = 0.19  
Table 4. Correlation of plasma adipokines concentration with MS criteria and target organs 
damage in patients with MS and NAFLD (n=86). * - significant correlations 
OSAS was diagnosed in 20 (24%) patients (Table 5). These patients had significantly higher 
blood pressure, BMI, WC, fasting insulin serum concentration and C-peptide. Obese 
patients with OSAS demonstrated significantly marked target organs damage signs (higher 
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level of albuminuria and lower GFR) in comparison with obese patients without OSAS. Also 
obese patients with CKD developed OSAS more frequent than obese patients without CKD 







Male/female 17/3 47/19 
Mean age, years old 45±10 43±11 
Mean blood pressure, mm/Hg 106±9 100±9 
BMI, kg/m2 39.8±7.9** 31.5±4.3 
WC, cm 125±17** 108±11 
HOMA-index 4.1±1.9* 3.1±1.9 
C-peptide, pmol/L 1337±422* 1092±384 
Leptin, ng/mL 36.7±29.9 25.3±23.0 
Adiponectin, μg/mL 20.4±10.8 21.2±19.1 
Insulin, μU/mL 16.9±7.8* 12.7±7.3 
Albuminuria, mg/24h 21.0 (12.0;38.4)* 10.3 (6.3;19.4) 
GFR, mL/min/1.73m2 81±17* 95±24 
Table 5. Clinical and laboratory characteristics of patients with MS and NAFLD (n=86) in 
case of OSAS presence or absence. *-P<0.05; **-P<0.001 
4. Discussion 
According to our data an increase of target organs damage in patients with MS and NAFLD 
leads to an increase of CKD and NASH development rate and albuminuria level. 
Relationship of NAFLD and albuminuria was also shown in other clinical invetigations. 
Hwang S.T. et al. examined 1361 patients with type 2 diabetes mellitus and prediabetes 
(Hwang et al., 2010). 
The patients with NAFLD had higher prevalence rates of microalbuminuria (6.3% vs 19%; 
P=0.001 in prediabetes, 4.5% vs 32.6%; P<0.001 in diabetes) and also had a greater albumin-
to-creatinine ratio (14.6 +/- 52.0 μg/mg Cr vs 27.7 +/- 63.9 μg/mg Cr; P=0.051 in 
prediabetes, 11.4 +/- 21.4 μg/mg Cr vs 44.7 +/- 76.4 μg/mg Cr; P<0.001 in diabetes) than 
those without NAFLD. NAFLD was associated with 3.66 (P=0.013) times higher rate of 
microalbuminuria in prediabetes patients and 5.47 (P=0.048) times higher in diabetes 
patients. Our patients with MS and NAFLD showed highest albuminuria level in the group 
with highest NASH prevalence rate. Leptin/adiponectin ratio raised significantly in 
observed by our team patients with MS and NAFLD when albuminuria level and NASH 
prevalence rate increased. It probably indicates that increased expression of tissue-
destructive adipokine – leptin is not combined with adequate plasma concentration increase 
of protective adipokine – adiponectin. It was shown that the increase of leptin/adiponectin 
ratio is associated with increase of visceral fat mass, MS prevalence (Kumagai et al., 2005) 
and severity of insulin resistance (Oda et al., 2008). 
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Both insufficient adiponectin effect and leptin hyperproduction predetermine the increase of 
insulin resistance. It reaches maximum level in the group of patients with NAFLD and CKD 
demonstrating highest values of fasting insulin serum concentration, C-peptide and HOMA-
index. Evidently insulin resistance in such patients is caused mainly by leptin excess 
(Anubhuti & Arora, 2008), which maximal plasma concentration registered in patients with 
NAFLD and CKD. Leptin contribution to insulin resistance of peripheral tissues 
intensification is more evident as NAFLD progresses and CKD develops, adiponectin 
plasma concentration and its tissue protective effect gradually decrease (this is also 
evidenced by our observation of significant leptin/adiponectin ratio increase). It should be 
noted that leptin mainly shows properties similar to insulin excess and hereby comes into 
synergic effect with it, in particular by inducing expression of profibrogenic chemokines in 
target tissues (e.g.  transforming growth factor beta (TGF-β)) leading to tissue fibrosis 
development. Currently, the role of leptin in kidney tissue firosis development is clear (Wolf 
& Ziyadeh, 2006), pathogenetic role of obesity as CKD risk factor in general population 
determined in several epidemiological investigations (Foster et al., 2008; Kramer et al., 2005) 
could be explained by consequences of hyperleptinemia (similar as adiponectin  
insufficiency). It was also shown that leptin directly increases fibrogenesis in liver tissue in 
patients with NAFLD. Ikejima K. et al. demonstrated leptin key role in stimulation of TGF-β 
mRNA expression in Kupffer cells and sinusoidal endothelial cells in rodents with 
genetically determined leptin and leptin receptor deficiency (Ikejima et al., 2005). Moreover, 
leptin augmented platelet derived growth factor-dependent proliferation of hepatic stellate 
cells by enhancing downstream intracellular signaling pathways. Hereby NAFLD and CKD 
progression in patients with MS is determined mainly by profibrogenic effect of leptin and 
excess of insulin. 
Along with indicated above, leptin and insulin induced endothelial dysfunction could stand 
as another common mechanism of NAFLD and CKD development. Increasing albuminuria– 
is a local kidney marker of endothelial dysfunction. It was proved, that hyperleptinemia 
directly related to microalbuminuria in patients with abdominal obesity (Ikee et al., 2008). 
Close associations of NAFLD with global impairment of endothelial function were 
estimated. Thus, examination of 250 obese children showed that presence of NAFLD entails 
more severe functional and anatomic changes in the arterial wall. Flow-mediated 
vasodilatation of brachial artery (one of the signs of endothelial dysfunction) was 
remarkably reduced and CIMT was increased in obese subjects with confirmed MS and 
NAFLD (Pacifico et al., 2010). Hypertensive patients with NAFLD have a reduced 
endothelium-dependent vasodilation and highest insulin resistance in comparison with 
hypertensive patients without NAFLD. In keeping with this, it is possible to hypothesize 
that liver steatosis may be considered a marker of vascular damage in essential hypertension 
(Sciacqua et al., 2010). Integrally, NAFLD presence in patients with MS is always combined 
with the most pronounced endothelial dysfunction, which mainly predetermines intensity 
of other target organs remodeling, including kidney. The role of hepatic endothelial cells 
impaired function, related to hyperleptinemia, insulin resistance and insufficient effects of 
adiponectin, in progression of NAFLD could not be completely excluded. Development of 
specific laboratory investigation methods is necessary to evaluate their contribution. 
Relationships between NAFLD and CKD revealed in this research in patients with MS could 
be explained by an imbalanced action of antagonistic adipokines – leptin and adiponectin – 
and combined with it the intensification of insulin resistance. Taking into consideration our 
correlation analysis data leptin plasma concentration directly correlates with body mass; in 
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parallel with it – insulin resistance and albuminuria. In addition hyperleptinemia is 
associated with an increased blood pressure. Hypertensive effect of leptin was confirmed in 
general population. During one of the phases of prospective population investigation - 
Copenhagen City Heart Study - new-onset hypertension was examined in 620 women and 
300 men who were normotensive in the previous examination, which was performed in 
1991-1994 (Asferg et al., 2010). Leptin plasma concentration was significantly associated 
with new-onset hypertension (odds ratio of 1.28 (1.08-1.53; P < 0.005) for 1 s.d. higher level 
of log-transformed leptin), whereas adiponectin was not significantly associated with new-
onset hypertension. Adiponectin plasma concentration directly correlated with 
concentration of HDL cholesterol, and correlated inversely with CIMT and atherogenic 
index. Our data matches generally accepted conception of adiponectin antiatherogenic 
properties and its ability to withstand intensification of metabolic disorders, particularly 
insulin resistance in patients with MS (Han et al., 2009). 
Direct correlation between adiponectinemia and De Ritis ratio demonstrated in our study 
shows inhibitory action of adiponectin on NAFLD progression rate. In case of NASH onset 
in such patients adiponectin plasma concentration and level of its expression by liver tissue 
significantly decrease (Jiang et al., 2009; Ma et al., 2009). Thereby leptin/adiponectin 
imbalance may be regarded as one of the most important mechanisms of organ damage 
including CKD and NAFLD in patients with MS. 
OSAS had a special place among other independent risk factors of CKD severity and 
progression in patients with MS and NAFLD examined by our team. Patients with OSAS 
showed maximum levels of insulin resistance markers and exactly those subjects 
demonstrated the highest albuminuria level and a lower level of estimated GFR in 
comparison with groups of patients with MS without OSAS. Recently OSAS has been 
considered as one of “most malignant” variant of MS, during which both target organ 
damage rate and severity of metabolic impairments could reach maximal intensity. Highest 
expression levels of adipokines with tissue-destructive effect, in particular – leptin were 
registered in patients with OSAS. Presence of direct significant correlation between leptin 
plasma concentration and apnea/hypopnea index was evaluated in patients with OSAS 
(Tokuda et al., 2008). Stepwise multiple regression analysis showed that BMI (r=0.807, 
p<0.0001), the percentage of time with less than 90% hemoglobin saturation level in total 
sleep time (%T<90)(r=0.399, p<0.001) and apnea/hypopnea index (r=0.552, p<0.001) were 
determinant factors for serum leptin levels. Thus, hyperleptinemia raised as OSAS severity 
and BMI increased. Among the patients who had successful surgical correction of OSAS 
(uvulopalatopharyngoplasty; or uvulopalatopharyngoplasty and tonsillectomy; or 
uvulopalatopharyngoplasty, tonsillectomy and radiofrequency ablation of the base of the 
tongue) leptin and other adipokines with similar effect (interleukin-6. tumor necrosis factor-
alfa) plasma concentration dramatically decreased, whereas adiponectin plasma 
concentration significantly increased after surgery (Adeseun & Rosas, 2010). 
Typical for OSAS adipokines hyperproduction leads to the enhancement of target organ 
damage development. It was confirmed in multiple clinical and epidemiological 
investigations. In this way OSAS is considered as one of CKD risk factors (Eun et al., 2010). 
Patients with OSAS demonstrate significantly lower estimated GFR in comparison with 
patients without OSAS (84.57 and 94.67 mL/min/1.73m2 respectively, P=0.037) 
(Fleischmann et al., 2010). Patients with estimated GFR <60 mL/min/1.73m2 show 6 times 
higher frequency of central apnea episodes in comparison with group of patients with 
estimated GFR  >60 mL/min/1.73m2. Presence of OSAS as concomitant condition in our 
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patients with NAFLD was associated with significant decrease of estimated GFR which was 
calculated using MDRD formula. Thereby this category of patients should be subjected to 
medical examination at first visit  for detection of early stages of CKD (assessment of 
albuminuria level, estimated GFR, including new markers for GFR estimation, particularly 
cystatin C). 
5. Conclusion 
The results of our study indicate that in patients with MS a relationship exists between 
NAFLD and CKD: NASH development is closely related to increase in albuminuria levels. 
Association of NAFLD and CKD in patients with MS may be explained by mutual 
mechanisms of onset and progression, among which should be mentioned hyperleptinemia, 
lack of adiponectin effects and related to it increase of insulin resistance. From this point of 
view all the patients with MS and NAFLD must be checked for CKD signs (albuminuria, 
serum creatinine, estimated GFR). Dynamical changes of these markers could play the role 
of efficacy indicators of integral therapeutic approaches, e.g. medications for treatment of 
obesity (orlistat), oral hypoglycemic agents (metformin), antihyperlipidemic agents (statins, 
fenofibrate) and also several antihypertensive drugs (angiotensin receptor blockers). 
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